Ultragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases.
Industries BiotechnologyHealth CarePharmaceuticalHeadquarters Regions San Francisco Bay Area, West Coast, Western US Founded Date 2010 Founders Emil D. Kakkis, John Klock Operating Status Active Last Funding Type Post-IPO Equity Legal Name Ultragenyx Pharmaceutical Inc.
Stock Symbol NASDAQ:RARE Company Type For Profit
Number of Exits
Contact Email info@ultragenyx.com Phone Number +1 415 483 8800
Ultragenyx Pharmaceutical develops therapeutics for rare diseases, sometimes referred to as Orphan products. Ultragenyx is a efficient and effective development strategies are essential for success in the rare disease space, in which information may be incomplete or ambiguous, and few development precedents exist. The management team's
experience in selecting and developing products with clear mechanisms of action for untreated rare diseases will help Ultragenyx create life-changing therapeutics by leveraging existing yet undeveloped science for these little-known indications.